Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone dry-powder inhalation - Dura/Spiros

Drug Profile

Beclometasone dry-powder inhalation - Dura/Spiros

Alternative Names: Beclomethasone dry-powder inhalation - Dura/Spiros; Beclomethasone Spiros

Latest Information Update: 02 Oct 2000

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dura Pharmaceuticals
  • Developer Dura Pharmaceuticals; Spiros Development Corporation II
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 02 Oct 2000 Discontinued-III for Asthma in USA (Inhalation)
  • 07 Feb 2000 Phase-III clinical trials for Asthma in USA (Inhalation)
  • 15 Feb 1999 A study in healthy volunteers has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top